(Q37625177)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19879420%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

review article

1 reference

title

Clusterin (CLU) and prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19879420%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19879420%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Saverio Bettuzzi

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19879420%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

Federica Rizzi

series ordinal

1

1 reference

21 August 2017

Saverio Bettuzzi

series ordinal

2

1 reference

21 August 2017

publication date

1 January 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19879420%20AND%20SRC:MED&resulttype=core&format=json

Advances in Cancer Research

11 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19879420%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

volume

105

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19879420%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

page(s)

1-19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19879420%20AND%20SRC:MED&resulttype=core&format=json

Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention.

11 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Identification of an androgen-repressed mRNA in rat ventral prostate as coding for sulphated glycoprotein 2 by cDNA cloning and sequence analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Genetic inactivation of ApoJ/clusterin: effects on prostate tumourigenesis and metastatic spread.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Prostate cancer: where we have been, where we are, where we are going

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Direct transactivation of the anti-apoptotic gene apolipoprotein J (clusterin) by B-MYB

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Clusterin-mediated apoptosis is regulated by adenomatous polyposis coli and is p21 dependent but p53 independent.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Inhibition of spontaneous and androgen-induced prostate growth by a nonhypercalcemic calcitriol analog

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Delayed activation of insulin-like growth factor-1 receptor/Src/MAPK/Egr-1 signaling regulates clusterin expression, a pro-survival factor.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

1 reference

7 January 2021

The role of prevalence in the diagnosis of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Antisense targets to enhance hormone and cytotoxic therapies in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Prostate cancer in a transgenic mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Nerve growth factor and epidermal growth factor stimulate clusterin gene expression in PC12 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Identification of Epigenetically Silenced Genes in Tumor Endothelial Cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Regional estimates of prostate cancer burden in Italy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Protective effect of green tea against prostate cancer: A case‐control study in southeast China

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Transforming growth factor beta regulates clusterin gene expression via modulation of transcription factor c-Fos

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Pathobiology of autochthonous prostate cancer in a pre‐clinical transgenic mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

IR-inducible clusterin gene expression: a protein with potential roles in ionizing radiation-induced adaptive responses, genomic instability, and bystander effects

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Clusterin Biogenesis Is Altered during Apoptosis in the Regressing Rat Ventral Prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Hepatitis delta virus epigenetically enhances clusterin expression via histone acetylation in human hepatocellular carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Up-regulation of the clusterin gene after proteotoxic stress: implication of HSF1-HSF2 heterocomplexes.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Oncogenic HRAS suppresses clusterin expression through promoter hypermethylation.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Stress-induced transcription of the clusterin/apoJ gene.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Clusterin isoforms differentially affect growth and motility of prostate cells: possible implications in prostate tumorigenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Induction of clusterin/apoJ expression by histone deacetylase inhibitors in neural cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Designing a randomized phase I/II prostate cancer chemoprevention trial using 1alpha-hydroxy-24-ethyl-cholecalciferol, an analogue of vitamin D3.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Modulation of different clusterin isoforms in human colon tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Clusterin is epigenetically regulated in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Transforming growth factor beta (TGF beta)-induced nuclear localization of apolipoprotein J/clusterin in epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Interaction of transforming growth factor beta receptors with apolipoprotein J/clusterin

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Overexpression of clusterin in human breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

ONCOMINE: a cancer microarray database and integrated data-mining platform

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

A novel gene signature for molecular diagnosis of human prostate cancer by RT-qPCR.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Clusterin: physiologic and pathophysiologic considerations.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Clusterin mediates TRAIL resistance in prostate tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Essential requirement of apolipoprotein J (clusterin) signaling for IkappaB expression and regulation of NF-kappaB activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Clusterin (SGP-2, ApoJ) expression is downregulated in low- and high-grade human prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Clusterin overexpression in both malignant and nonmalignant prostate epithelial cells induces cell cycle arrest and apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Intracellular clusterin induces G2-M phase arrest and cell death in PC-3 prostate cancer cells1.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Molecular classification of green tea catechin-sensitive and green tea catechin-resistant prostate cancer in the TRAMP mice model by quantitative real-time PCR gene profiling.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Epigenetic regulation of clusterin/apolipoprotein J expression in retinal pigment epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Inhibition of NF-kappaB-dependent Bcl-xL expression by clusterin promotes albumin-induced tubular cell apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Transcriptional basis of KRAS oncogene-mediated cellular transformation in ovarian epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Myc-transformed epithelial cells down-regulate clusterin, which inhibits their growth in vitro and carcinogenesis in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Prostate-specific antigen in the early detection of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

The influence of finasteride on the development of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Screening for prostate cancer: opportunities and challenges

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Integrative molecular concept modeling of prostate cancer progression.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Clusterin/apolipoprotein J in human aging and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Regulation of clusterin/apolipoprotein J, a functional homologue to the small heat shock proteins, by oxidative stress in ageing and age-related diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Molecular targets for cancer chemoprevention

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Expression of clusterin in human pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Up-regulated expression of cytoplasmic clusterin in human ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

Loss of clusterin both in serum and tissue correlates with the tumorigenesis of esophageal squamous cell carcinoma via proteomics approaches.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2809%2905001-5

7 January 2021

10.1016/S0065-230X(09)05001-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19879420%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference